Lipids in Health and Disease (Oct 2010)

Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting

  • Mokuno Hiroshi,
  • Hiki Makoto,
  • Sumiyoshi Katsuhiko,
  • Kiyanagi Takashi,
  • Tanimoto Kosei,
  • Kume Atsumi,
  • Miyauchi Katsumi,
  • Shimada Kazunori,
  • Miyazaki Tetsuro,
  • Okazaki Shinya,
  • Sato Hitoshi,
  • Kurata Takeshi,
  • Daida Hiroyuki

DOI
https://doi.org/10.1186/1476-511X-9-122
Journal volume & issue
Vol. 9, no. 1
p. 122

Abstract

Read online

Abstract Background The association between modulation of detailed lipoprotein profiles and cholesterol ester transfer (CET) activity by peroxisome proliferator-activated receptor (PPAR)-a agonists in patients with coronary artery disease remains unclear. We assessed lipid profiles, plasma CET activity, and in-stent intimal hyperplasia after fenofibrate treatment in patients who underwent elective coronary stenting. Methods Forty-three consecutive patients who underwent elective coronary stenting were randomized to the fenofibrate group (300 mg/day for 25 weeks, n = 22) or the control group (n = 21). At baseline and follow up, CET activity and lipoprotein profiles were measured, and quantitative coronary angiography was performed. Results In the fenofibrate group, the levels of large very low-density lipoprotein cholesterol, and small low-density lipoprotein (LDL) cholesterol decreased and those of small high-density lipoprotein (HDL) cholesterol increased. Besides, CET activity decreased independent of the effect of fenofibrate on total and LDL cholesterol. The reduction of CET activity significantly correlated with the increase in LDL particle size (r = 0.47, P = 0.03) and the decrease of triglycerides in large HDL subclasses (r = 0.48, P = 0.03). Although there were no significant differences in restenosis parameters between the two groups, low CET activity significantly correlated with the inhibition of neointimal hyperplasia (r = 0.56, P = 0.01). Conclusions Fenofibrate inhibited CET activity and thereby improved atherogenic lipoprotein profiles, and reduced intimal hyperplasia after coronary stenting.